Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Aderis Drug Slows Ventricular Rate In Atrial Fibrillation Study

Nov. 12, 2003

By Aaron Lorenzo

Aradigm Adds To Cash Position With $13.5M Private Placement

Nov. 12, 2003

By Aaron Lorenzo

Agencourt Awarded $27M For Sequencing Project Selection

Nov. 10, 2003

By Aaron Lorenzo

Agencourt Awarded $27M For Sequencing Project Selection

Nov. 10, 2003

By Aaron Lorenzo

Climbing Through The Window: Pharmion, NitroMed Price IPOs

Nov. 7, 2003

By Aaron Lorenzo

The industry increased its number of publicly traded companies Thursday as Pharmion Corp. and NitroMed Inc. priced their initial public offerings. (BioWorld Today)

Climbing Through The Window: Pharmion, NitroMed Price IPOs

Nov. 7, 2003

By Aaron Lorenzo

The industry increased its number of publicly traded companies Thursday as Pharmion Corp. and NitroMed Inc. priced their initial public offerings. (BioWorld Today)

NeuroMed Gets $32M In Third Round To Push Pain Product

Nov. 5, 2003

By Aaron Lorenzo

NeuroMed Gets $32M In Third Round To Push Pain Product

Nov. 5, 2003

By Aaron Lorenzo

CV Therapeutics Stock Drops On Ranexa Approvable Letter

Nov. 3, 2003

By Aaron Lorenzo

CV Therapeutics Inc. received a mixed bag of news related to Ranexa, its lead compound for chronic angina, and investors took the news badly as the company's stock slipped 21.7 percent Friday. (BioWorld Today)

CV Therapeutics Stock Drops On Ranexa Approvable Letter

Nov. 3, 2003

By Aaron Lorenzo

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...